Why the study?
The emerging concept of tissue renin angiotensin system and newly discovered components have expanded its clinical and physiological relevance beyond classical endocrine regulation.
Key points are not available for this paper at this time.
Design
Review chapter
Answers are grounded in this paper and cite their sources.
Suggests novel tissue-specific RAS targets in cardiometabolic disease; extends understanding but leaves open clinical validation.
In its classical view, the renin angiotensin system (RAS) was defined as an endocrine system involved in blood pressure regulation and body electrolyte balance. However, the emerging concept of tissue RAS, along with the discovery of new RAS components, increased the physiological and clinical relevance of the system. Indeed, RAS has been shown to be expressed in various tissues where alterations in its expression were shown to be involved in multiple diseases including atherosclerosis, cardiac hypertrophy, type 2 diabetes (T2D) and renal fibrosis. In this chapter, we describe the new components of RAS, their tissue-specific expression, and their alterations under pathological conditions, which will help achieve more tissue- and condition-specific treatments.
No takes yet. Share an insight, caveat, or question.
Nehme et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: